Floatz Rating
B62/100
Confidence
Indicative
Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05935787CT.gov Cytoflavin in the Complex Rehabilitation of Stroke Patients | — | Completed | — | — | — |
NCT05297851CT.gov Cytoflavin in Combination With Reperfusion in Stroke Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lacto-Flavin (this asset) | POLYSAN Scientific & Technological Pharmaceutical Company | P3 | B · 62 |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Ticagrelor | Assistance Publique - Hôpitaux de Paris | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Lacto-Flavin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| AIDS | — | P4 | BB · 69 |
| Lactic Acidosis | — | P4 | BB · 69 |
| Lipodystrophy | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lacto-Flavin in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lacto-flavin-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →